Charlotte Kokocinski v. Arthur D. Collins, Jr.

850 F.3d 354, 2017 WL 780862, 2017 U.S. App. LEXIS 3681
CourtCourt of Appeals for the Eighth Circuit
DecidedMarch 1, 2017
Docket15-3519
StatusPublished
Cited by8 cases

This text of 850 F.3d 354 (Charlotte Kokocinski v. Arthur D. Collins, Jr.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Charlotte Kokocinski v. Arthur D. Collins, Jr., 850 F.3d 354, 2017 WL 780862, 2017 U.S. App. LEXIS 3681 (8th Cir. 2017).

Opinion

BEAM, Circuit Judge.

Charlotte Kokocinski brought a shareholder derivative action on behalf of Med-tronic, Inc., against current and former directors and officers of Medtronic, and against Medtronic as a nominal defendant. The district court 1 dismissed the action on the basis of a report by a special litigation committee, and we now affirm.

1. BACKGROUND

From roughly 2006 to 2008 Medtronic was the subject of a well-publicized controversy involving whistle-blower lawsuits, settlement and eorporate-compliance-and-governance agreements with federal agencies, and a congressional and media investigations. These events stemmed from Medtronic’s alleged improper promotion to physicians of the “off-label” use 2 of its “Infuse” product, a surgically implanted medical device that stimulates bone growth. Infuse was also the subject of a 2008 Public Health Notification by the Food and' Drug Administration (FDA). Medtronic’s revenue and share price suffered as a result of this negative publicity. In 2012, without first making a demand on Medtronic, Kokocinski brought a shareholder derivative action against Medtronic directors and officers (the individual defendants) seeking declaratory and injunctive relief and damages. The complaint alleged various bad acts and false and misleading statements by which the individual defendants violated § 14(a) of the Exchange Act, 15 U.S.C. § 78n(a), breached their fiduciary duties, wasted corporate assets, and had been unjustly enriched. Later that year, in response to demand letters and derivative complaints by other stockholders presenting similar allegations, Med-tronic’s board of directors (the Board) formed a special litigation committee (SLC) to investigate the claims. The district court dismissed Kokoeinski’s complaint without prejudice in 2013 for failing to establish demand futility. See Fed. R. *359 Civ. P. 23.1(b). 3 Kokocinski then exercised her statutory right to review Medtronic’s corporate records, Minn. Stat. § 302A.461, subd. 4, and in April 2014 she filed an amended complaint with bolstered allegations.

The SLC formed by Medtronic was initially composed of three members: John Matheson, a law professor and expert in corporate and business law; former Henne-pin County District Court Judge George McGunnigle; and former Governor of Utah Michael Leavitt. Of these three, only Governor Leavitt was a Board member. Governor Leavitt left the SLC in December 2012 due to the possible perception of in-terestedness due to his having formerly been the Secretary of Health and Human Services, which oversees the FDA, the agency tasked with approving Infuse. Professor Matheson and Judge McGunnigle proceeded to engage in an eighteen-month investigation in which they engaged an accountant, a loss-causation analyst, and an economist; retained independent legal counsel; reviewed over 2.6 million documents; and interviewed sixty individuals, including current and former directors, officers, and employees of Medtronic, Med-tronic sales representatives, consulting physicians, a physician who had been solicited to use Infuse, and one unaffiliated surgeon who had used the Infuse product. In May 2014, the SLC issued a 69-page report concluding that it would not be in Medtronic’s best interest to pursue litigation. It noted that setting forth detailed factual findings would not be in Medtronic’s interest as Medtronic was currently involved in securities fraud and personal injury litigation involving similar allegations. Further it noted that it did not find support for the allegations and rejected the claims of the demand letters and derivative complaints.

The individual defendants, Med-tronic, and the SLC (even though it was not a named party to the litigation and had not filed a motion to intervene) each brought a motion to dismiss Kokocinski’s amended complaint on the basis of the SLC’s report. Applying Minnesota law, the district court determined the SLC’s investigation and methodologies warranted deference to its report under the business-judgment rule (BJR), and it granted the motions. 4 After entering judgment, the district court denied Kokocinski’s motion for relief from, or to amend, the judgment, and entered judgment on that motion as well. Kokocinski timely appeals from both memorandum orders and judgments, arguing that (1) the SLC was not properly formed; (2) it was not entitled to deference *360 under the BJR; and (8) the district court committed reversible error in failing to permit the parties to engage in discovery.

II. DISCUSSION

Our standard of review on appeal depends on the proper way in which to construe the defendants’ motions made on the basis of the SLC’s report. The district court determined the motions should. be construed as akin to a motion seeking voluntary dismissal of a shareholder’s derivative action under Rule 23.1(c), borrowing from Rule 56 procedures. Borrowing a term from other cases, we will refer to the defendants’ motions collectively as a “motion to terminate” the litigation. Kokocin-ski argues that the motion should have been converted to a Rule 56 motion for summary judgment warranting de novo review because it relied on the SLC’s report, a matter outside the pleadings. 5 This is a matter of first impression for our circuit. 6

The First Circuit, applying Delaware law, has followed the lead of Delaware courts and classified such a motion as a “hybrid summary judgment motion for dismissal,” reviewing de novo. Sarnacki v. Golden, 778 F.3d 217, 221 (1st Cir. 2015) (quoting Zapata Corp. v. Maldonado, 430 A.2d 779, 787 (Del. 1981)). Other circuits have regarded it as a Rule 56 motion, also reviewing de novo. E.g., Booth Family Trust v. Jeffries, 640 F.3d 134, 139 (6th Cir. 2011); Gaines v. Haughton, 645 F.2d 761, 769 (9th Cir. 1981), overruled on other grounds by Churchill v. The F/V Fjord (In re McLinn), 739 F.2d 1395, 1397 (9th Cir. 1984) (en banc). The Eleventh Circuit, looking to Delaware law, has instead construed a motion to terminate as one arising under Rule 23.1 and applied an abuse-of-discretion standard of review. Peller v. S. Co., 911 F.2d 1532, 1536 (11th Cir. 1990). Minnesota courts have not characterized such motions consistently. See Janssen, 662 N.W.2d at 889-90.

We agree that because of its reliance on the SLC’s report, and because it does not go to the adequacy of the pleadings, the defendants’ motion cannot be construed as a motion under Rule 12(b)(6). On the other hand, a ruling granting the motion would not go to the merits of Kokoeinski’s claims, and so it does not fit neatly into the summary-judgment box either.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
850 F.3d 354, 2017 WL 780862, 2017 U.S. App. LEXIS 3681, Counsel Stack Legal Research, https://law.counselstack.com/opinion/charlotte-kokocinski-v-arthur-d-collins-jr-ca8-2017.